Gilead Sciences Inc. (NASDAQ:GILD) Sovaldi was approved in December by the FDA and has been shown to have cure rates higher than 80%. As many as 3.2 million people have the disease, and 20% to 35% of them are estimated to be enrolled in Medicaid, according to the trade group for the managed-care plans, which would make at least 600,000 beneficiaries candidates for the drug. Gilead reported this month that U.S. sales of the drug reached $2.1 billion in the first quarter of 2014, and 7%, or $160 million, came from state Medicaid programs. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $74.67 moved to $76.38 on last trade day and at the end of the day closed at $76.24. Company price to sales ratio in past twelve months was calculated as 8.58 and price to cash ratio as 17.09. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 4.64%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares advanced 4.71% in last trading session and ended the day on $7.33. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -59.26%.
MannKind Corporation (NASDAQ:MNKD)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Tuesday, Stock Ratings Network reports. They currently have a $6.75 target price on the stock. Zacks‘s price target points to a potential upside of 6.13% from the company’s current price. MannKind Corporation (NASDAQ:MNKD) shares moved up 3.22% in last trading session and was closed at $6.41, while trading in range of $6.17 – $6.44. MannKind Corporation (NASDAQ:MNKD) year to date (YTD) performance is 23.27%.
Stock in XOMA Corp. (NASDAQ:XOMA) got an upgrade from an analyst at MLV & Co. The market response to one analyst’s improved outlook may appear excessive, but XOMA may have also been due for a rebound following a lengthy decline over the last two months that had several technical signs potentially indicating the stock was oversold. XOMA Corp (NASDAQ:XOMA) weekly performance is 3.15%. On last trading day company shares ended up $4.59. XOMA Corp (NASDAQ:XOMA) distance from 50-day simple moving average (SMA50) is -22.86%. Analysts mean target price for the company is $9.25.